AUPH's Dry Eye Syndrome Study Fails, KPTI's SEAL Study Hits Goal, REGN Halts Rare Bone Disease Trial

Today's Daily Dose brings you news about Aurinia's disappointing results from its dry eye syndrome trial, CureVac's encouraging data from phase I study of COVID-19 vaccine candidate, Jounce discontinuing enrollment in NSCLC trial, Karyopharm's promising results from SEAL study, Regeneron pausing fibrodysplasia ossificans progressive trial on reports of deaths, and Santhera trimming its workforce.

from RTT - Biotech https://ift.tt/2HWbbte
via IFTTT